A detailed history of Avidity Partners Management LP transactions in Scynexis Inc stock. As of the latest transaction made, Avidity Partners Management LP holds 1,448,728 shares of SCYX stock, worth $1.46 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
1,448,728
Previous 1,448,728 -0.0%
Holding current value
$1.46 Million
Previous $2.9 Million 25.51%
% of portfolio
0.13%
Previous 0.14%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.56 - $2.24 $201,683 - $289,596
129,284 Added 9.8%
1,448,728 $3.23 Million
Q3 2023

Nov 14, 2023

SELL
$1.93 - $3.64 $809,229 - $1.53 Million
-419,290 Reduced 24.11%
1,319,444 $3.01 Million
Q2 2023

Aug 14, 2023

BUY
$2.38 - $3.67 $4.14 Million - $6.38 Million
1,738,734 New
1,738,734 $5.13 Million
Q3 2022

Nov 14, 2022

BUY
$1.83 - $2.93 $331,369 - $530,552
181,076 Added 18.87%
1,140,600 $2.74 Million
Q2 2022

Aug 15, 2022

BUY
$1.77 - $3.87 $735,401 - $1.61 Million
415,481 Added 76.37%
959,524 $1.79 Million
Q1 2022

May 16, 2022

SELL
$3.56 - $6.66 $6.04 Million - $11.3 Million
-1,695,235 Reduced 75.7%
544,043 $2.13 Million
Q4 2021

Feb 14, 2022

BUY
$4.94 - $7.69 $885,633 - $1.38 Million
179,278 Added 8.7%
2,239,278 $13.7 Million
Q2 2021

Aug 16, 2021

BUY
$6.5 - $9.97 $5.18 Million - $7.94 Million
796,231 Added 63.0%
2,060,000 $15.2 Million
Q1 2021

May 17, 2021

BUY
$6.93 - $9.63 $60,769 - $84,445
8,769 Added 0.7%
1,263,769 $10 Million
Q4 2020

Feb 16, 2021

BUY
$4.28 - $7.87 $5.37 Million - $9.88 Million
1,255,000 New
1,255,000 $9.6 Million

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $33M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.